AIM Company Profile

Below is the information we hold on the AIM company you have chosen to view. As a registered user, you can can view the Share Price, any public documents or presentations on the AIM company plus any additional details. Click on the share price ‘Block’ and you can view extended charting and share information. ‘Bookmark’ the company to your own portfolio, print off the page details and download as a ‘pdf’. You can also rate this AIM company by simply clicking the ‘star’ rating. If we hold news on this company, relevant articles will be displayed for you to view. Note: All share information is subject to a 15min. delay.

TRADE SHARES IN THIS AIM COMPANY

ALLERGY THERAPEUTICS

4.0
  1. Pharmaceuticals & Biotechnology
  2. » ALLERGY THERAPEUTICS
Share Price
Share Activity:
×
Key metrics
Market Cap
PE Ratio
PEG Ratio
EPS
Beta
Dividends
Dividend Rate
Dividend Yield
Ex Dividend Date
50 Days Moving Average
200 Days Moving Average
Key data
Symbol
Name
Bid
Ask
Last Price
Change
52 Week Low
52 Week High
Symbol Name Last Price Change % Change Day Low Day High

Click to View Charting

Research
You must be logged in to see this info
Key Company Info.
Company Description:

Who we are

We are a visionary immunology business with specialist experience in the research and development of allergy treatments. We have a well-established commercial presence in Europe and are focused on the US market opportunity.

What we do

We specialise in the diagnosis and treatment of allergy. Allergy vaccination is a successful treatment that deals with the underlying cause of allergies and not just the symptoms1.

We mainly sell our products in European countries and our pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, as well as a peanut allergy vaccine in preclinical development. Adjuvant systems to boost performance of vaccines outside allergy are also under evaluation.

What makes us different

Our ultra-short course treatments consist of 4-6 injections over the course of 3-6 weeks compared to daily tablets or an average treatment in the market of a 12-15 course of injections. Our approach offers the simplicity of 4-6 injections, increased tolerability and demonstrated efficacy2.

Our adjuvant technologies improve therapies by allowing them to increase efficacy. We are further developing this concept in our specialist business, Bencard Adjuvant Systems; improving health and evaluating vaccinations for infectious diseases and cancer treatments.

Our values have created a culture based around vision, commitment and humanity. We take extraordinary ideas and bring them to market - enhancing treatments and transforming people's lives.

Active: Trading
EPIC:

AGY

List date: 11th October 2004 00:00
Region:

South East

Advisors
Nominated Advisor:

Panmure Gordon (UK) Limited

Broker:

Panmure Gordon (UK) Limited

Contact Information
You must be logged in to see this info

If this profile is about your AIM company, but the information is limited you can add to the information we hold. The company displayed HERE is a typical example of the type of information we can display about your company. Good promotion of your AIM listed company is critical for exposure to potential investors and liquidity in shares. Get in touch HERE if you would like to know more about how we can help promote your AIM listed company.